早期类风湿及未分化关节炎患者糖皮质激素停用:BeSt与IMPROVED研究事后分析
该事后分析评估了BeSt和IMPROVED两项达标治疗研究中初始接受泼尼松递减联合csDMARDs治疗的早期类风湿及未分化关节炎患者糖皮质激素停用的成功率及相关因素。结果显示首次停用后约40%患者直接失去疾病控制,再次停用后约50%患者出现病情复发;基线及停用时较低DAS与首次停用成功相关,停用时DAS可能为停药时机提供指导。
要点
- 首次停用糖皮质激素后约40%患者直接失去疾病控制。
- 再次停用后约50%患者出现病情复发。
- 基线及停用时较低DAS与首次停用成功相关。
核心结论
- 首次糖皮质激素停用导致约40%患者直接失去疾病控制,再次停用后约50%患者出现病情复发。
研究设计与样本
- 对BeSt(目标DAS≤2.4)和IMPROVED(目标DAS<1.6)两项达标治疗研究进行事后分析,纳入初始接受泼尼松递减高剂量联合csDMARDs治疗的患者;BeSt中维持DAS≤2.4达28周时停用泼尼松,IMPROVED中DAS<1.6时即停用;停用后下次访视维持目标视为成功。
主要发现
- BeSt研究中首次停用泼尼松后40%(47/93)患者复发,其余60%(56/93)中38%后续需重新使用;重新使用后再次停用者47%(17/35)再次复发。
- IMPROVED研究中首次停用后39%(158/400)患者复发,其余61%(242/400)中40%后续需重新使用;再次停用后49%(68/139)患者复发。
- 仅在IMPROVED研究中再次停用成功率低于首次停用(OR 0.60,p=0.01);BeSt研究中无显著差异(OR 0.71,p=0.45)。
- 基线及停用时较低DAS与首次停用成功相关;IMPROVED研究中男性与首次停用成功相关。
关键数值与推荐
- BeSt研究目标DAS≤2.4,泼尼松在DAS≤2.4维持28周时停用;IMPROVED研究目标DAS<1.6,DAS<1.6时即停用。
- 首次停用泼尼松后BeSt中40%(47/93)复发,IMPROVED中39%(158/400)复发。
临床怎么用
- 停用时DAS可能为糖皮质激素桥接治疗时长提供个体化指导。
- 常规基线特征似乎不足以个体化确定临时糖皮质激素桥接治疗的持续时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the success rate of glucocorticoid discontinuation and to study which factors are associated with successful discontinuation. METHODS: Data from two treat-to-target studies, BeSt (target Disease Activity Score (DAS) ≤2.4) and IMPROVED (target DAS <1.6), were evaluated for all patients initially treated with a tapered high dose of prednisone with conventional synthetic disease-modifying antirheumatic drugs. Prednisone was discontinued when DAS ≤2.4 was maintained for 28 weeks in BeSt and as soon as DAS was <1.6 in IMPROVED. Discontinuation was considered successful if the target was maintained at the next visit. Logistic regression analyses were performed to identify predictors of successful discontinuation. A mixed effects logistic regression model was used to assess whether primary versus secondary discontinuation was as successful. RESULTS: In the BeSt study, 40% (47 of 93) of patients flared after primary prednisone discontinuation, and of the other 60% (56 of 93), 38% had to restart later. Of those who restarted (secondary discontinuation), 47% (17 of 35) again flared. In IMPROVED, after primary discontinuation 39% (158 of 400) flared, and of the other 61% (242 of 400), 40% had to restart later. After secondary discontinuation 49% (68 of 139) flared. Only in IMPROVED a secondary attempt was less successful (BeSt OR 0.71, p=0.45; IMPROVED OR 0.60, p=0.01). A lower DAS both at baseline and stop visit and male gender (in IMPROVED) were associated with successful primary discontinuation. CONCLUSION: Primary glucocorticoid discontinuation resulted in direct loss of disease control in approximately 40% and secondary in 50% of patients. 'Standard' baseline characteristics seem insufficient to personalise the duration of temporary glucocorticoid bridging, but the DAS at the time of discontinuation might provide guidance.
引用
- Maassen JM, Dos Santos Sobrín R, Bergstra SA, et al. Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. Ann Rheum Dis. 2021. PMID: 34049858. doi:10.1136/annrheumdis-2021-220403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。